Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 161-169

  Kirkham, Bruce W ^a   Wasko, Mary Chester ^b,c   Hsia, Elizabeth C ^d,e   Fleischmann, Roy M ^f   Genovese, Mark C ^g   Matteson, Eric L ^h   Liu, Hongjuan ^c   Rahman, Mahboob U ^c,d,i  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WESTERN PENNSYLVANIA HOSPITAL   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g STANFORD UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; GOLIMUMAB; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LOW DENSITY LIPOPROTEIN; METHOTREXATE; PLACEBO; STROMELYSIN; VASCULOTROPIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-TNF; CARDIOVASCULAR DISEASE; LIPIDS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIPIDS; MALE; METHOTREXATE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889665878     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202089     Document Type: Article

References (32)

1. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196-202. (Pubitemid 36666340)
2. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45. (Pubitemid 34016192)
3. Galarraga B, Belch JJ, Pullar T, et al. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol 2010;37:521-8.
4. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum 2001;44:2707-10. (Pubitemid 34016188)
5. Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002;23:376-83. (Pubitemid 35204198)
6. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006;24:309-12. (Pubitemid 44151152)
7. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5. (Pubitemid 40193632)
8. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
9. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001;44:2761-7. (Pubitemid 34016195)
10. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75. (Pubitemid 27029945)
11. Janssen Biotech, Inc.Simponi: Package insert. Horsham, PA: Janssen Biotech, Inc, 2011.
12. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
13. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
14. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008;75:22-4.
15. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-6. (Pubitemid 46067823)
16. Wijbrandts CA, van Leuven SI, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316-21.
17. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem 2004;50:1189-200. (Pubitemid 38824227)
18. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002;48:171-80. (Pubitemid 34272531)
19. Atzeni F, Turiel M, Caporali R, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010;9:835-9.
20. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22.
21. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008;9:1121-8. (Pubitemid 351721750)
22. Pollono EN, Lopez-Olivo MA, Lopez JA, et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:947-55.
23. Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8. (Pubitemid 47201685)
24. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:414-19. (Pubitemid 43989884)
25. Dahlqvist SR, Engstrand S, Berglin E, et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006;35:107-11.
26. Del Porto F, Lagana B, Nofroni I, et al. Effects of tumour necrosis factor alpha blockade on lipid profile in active rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1626-27. (Pubitemid 47500593)
27. Allanore Y, Kahan A, Sellam J, et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006;365:143-8. (Pubitemid 43196430)
28. Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010;69:1310-14.
29. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31:451-6.
30. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
31. Mathieu S, Pereira B, Dubost JJ, et al. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 2013;52:204-9.
32. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:705-10.